PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Novel Preclinical Research Tools Provide Humanized Immune Response to Advance Immunotherapeutic Development, Live Webinar Hosted by Crown Bioscience

Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces a live webinar to be presented by Dr. Michelle Mack, Director of Global Scientific Engagement, entitled “Beyond Syngeneics – Novel Tools for Addressing Human Specificity in Immuno-Oncology.”
Checkpoint inhibitors like anti-PD-1, anti-PD-L1, and anti-CTLA-4 have revolutionized cancer treatment and have recently gained approval in several cancer types. Despite their potential, immunotherapies face significant development challenges due to the specificity and complexity of the human immune system upon which they act. Crown Bioscience has generated innovative research models to address these obstacles early during preclinical drug development.
This webinar will introduce novel tools for investigating human immune response in immunocompetent systems. This platform includes models that express humanized immune checkpoint inhibitors and ligands created via CRISPR/Cas9 gene editing. The validation of the platform will be detailed to demonstrate its reliability and utility to inform immuno-oncology efficacy studies.
“Crown Biosciences recognizes the importance of providing innovative tools for the evaluation of new therapies, especially in complex applications like immuno-oncology,” said Laurie Heilmann, Chief Business Officer at Crown Bioscience. “By attending this webinar, researchers will learn how to use our unique platform to transform their preclinical immunotherapeutic programs.”
Join Dr. Mack on Tuesday, October 31 at 10:00 am EDT for an informative session. For details or to register for this complimentary event, visit: Are You Choosing the Right Model? A Guide to Selecting Your Next Immuno-Oncology Model.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026